Posts tagged as

Paul Crispen MD

UF Health Urologists Working to Expand Options for BCG-Unresponsive Bladder Cancer

“Other treatments in the bladder are typically administered once a week for six weeks,” Crispen said. “Offering longer intervals between treatments is favorable for these patients, leading to fewer office visits, co-pays, catheterizations and everything else that goes along with the process.” If successful, Crispen said new treatment agents may even replace intravesical BCG as the primary therapy for high-risk NMIBC. BCG treatments are highly toxic, with potentially serious complications; in fact, fewer than 20% of patients are able to tolerate all doses of BCG maintenance therapy.

UF Health Developing New Bladder Cancer Therapeutic

“The new treatment would combine this antibody with a very potent form of chemotherapy,” said Paul Crispen, MD, an associate professor in the UF Department of Urology. “This antibody drug conjugate could potentially deliver the chemotherapy selectively to areas of cancer to increase efficacy and limit toxicity.”

UF Health Urology Podcasts/Videos

The official podcast of UF Health provides engaging insight on today’s trending health care topics. Earn CME credits while learning about clinical issues and research advances from experts at UF Health Shands Hospital, one of the nation’s top academic health centers. Subscribe to UF Health MedEd Cast and join the conversation!

graphic if US NEWS best hospital